BNP Paribas Asset Management
BCYC

BNP Paribas Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

BNP Paribas Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-568,225
Closed -$4.02M – 2264
2025
Q4 		$4.02M Buy
+568,225
New +$4.19M ﹤0.01% 896
2025
Q3 		– Sell
-1,041,456
Closed -$7.24M – 1887
2025
Q2 		$7.24M Sell
1,041,456
-178,232
-15% -$1.42M 0.02% 515
2025
Q1 		$10.4M Buy
1,219,688
+64,037
+6% +$755K 0.03% 440
2024
Q4 		$16.2M Buy
1,155,651
+395,764
+52% +$8.48M 0.04% 383
2024
Q3 		$17.2M Sell
759,887
-128,194
-14% -$2.96M 0.04% 336
2024
Q2 		$18M Buy
888,081
+4,976
+0.6% +$112K 0.05% 312
2024
Q1 		$22M Buy
883,105
+100,107
+13% +$2.13M 0.06% 292
2023
Q4 		$14.2M Buy
782,998
+142,116
+22% +$2.35M 0.04% 362
2023
Q3 		$12.9M Buy
640,882
+131,572
+26% +$3.01M 0.04% 347
2023
Q2 		$13M Sell
509,310
-10,263
-2% -$238K 0.04% 354
2023
Q1 		$11.1M Buy
519,573
+218,605
+73% +$5.48M 0.04% 407
2022
Q4 		$8.91M Buy
+300,968
New +$8.07M 0.03% 437

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BNP Paribas Asset Management's BCYC Position: Q1 2026 in Review

BNP Paribas Asset Management sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 568,225 shares — an estimated $4.02M sold.

BNP Paribas Asset Management first reported a position in BCYC in Q4 2022 and held it in 12 quarters. The position peaked at $22M in Q1 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • BNP Paribas Asset Management reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 568,225 Bicycle Therapeutics shares in Q1 2026, an estimated $4.02M.
  • BNP Paribas Asset Management first reported a position in Bicycle Therapeutics in Q4 2022 and held it in 12 quarters.
  • BNP Paribas Asset Management's Bicycle Therapeutics position peaked at $22M in Q1 2024.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.